摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

氨基丙酮盐酸盐 | 7737-17-9

中文名称
氨基丙酮盐酸盐
中文别名
氨基乙酮盐酸盐
英文名称
1-aminopropan-2-one hydrochloride
英文别名
aminoacetone hydrochloride;1-aminoacetone hydrochloride;1-Aminopropan-2-one;hydron;chloride
氨基丙酮盐酸盐化学式
CAS
7737-17-9
化学式
C3H7NO*ClH
mdl
MFCD00056125
分子量
109.556
InChiKey
RUCLDQBBIJKQHO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    73-74 °C
  • 溶解度:
    DMF:25mg/mL; DMSO:15mg/mL;乙醇:10mg/mL; PBS(pH 7.2):10 mg/mL

计算性质

  • 辛醇/水分配系数(LogP):
    -0.82
  • 重原子数:
    6
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.666
  • 拓扑面积:
    43.1
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2922399090
  • WGK Germany:
    3
  • 危险性防范说明:
    P280,P305+P351+P338,P310
  • 危险性描述:
    H302,H315,H319,H332,H335
  • 储存条件:
    室温且干燥

SDS

SDS:33d5ea6872d51712913cb9b0e17e3ce3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Aminopropan-2-one, HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Aminopropan-2-one, HCl
CAS number: 7737-17-9

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H8ClNO
Molecular weight: 109.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Aminoacetone hydrochloride 是最简单的单肽,也是苏酸和甘酸代谢的中间产物。此外,它还是敏感胺氧化酶(SSAO)的内源性底物,可用来检测SSAO活性。

反应信息

  • 作为反应物:
    描述:
    氨基丙酮盐酸盐1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以88%的产率得到3-(4-benzyloxy-phenyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-(2-oxo-propyl)-propionamide
    参考文献:
    名称:
    Novel high affinity quinoline-based kinase ligands
    摘要:
    基于喹啉的细胞周期蛋白依赖激酶2抑制剂,包括这些抑制剂的组合物,以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对治疗疾病或疾病症状有用。该发明还提供了制备CDK-2抑制剂化合物的方法,抑制CDK-2的方法,以及治疗疾病或疾病症状的方法。
    公开号:
    US20080045568A1
  • 作为产物:
    描述:
    (R)-N-tert-butanesulfinyl 2,2-dimethoxypropylamine盐酸 作用下, 以 甲醇 为溶剂, 反应 1.0h, 以90%的产率得到氨基丙酮盐酸盐
    参考文献:
    名称:
    重排ñ -叔-Butanesulfinylα-晕与醇盐亚胺到ñ -叔-Butanesulfinyl 2-氨基缩醛作为的前体ñ和-protected Ñ -Unprotectedα氨基羰基化合物
    摘要:
    的反应ñ -叔-butanesulfinylα卤代亚胺与得到新的醇盐ñ -叔-butanesulfinyl 2-氨基缩醛以良好至优异的产量。这些ñ -叔-butanesulfinyl 2-氨基缩醛是用于相应的将TMSOTf促进的合成前体的便利ñ -保护的α氨基醛和酮,以及为2-氨基乙缩醛盐酸盐和α-盐酸促进的合成氨基酮和α-氨基醛盐酸盐的收率高。通过这种方法,实现了(S)-卡西酮盐酸盐的非对称合成(er 94:6)。
    DOI:
    10.1021/jo300752c
点击查看最新优质反应信息

文献信息

  • Tetrahydrochromenoimidazoles as Potassium-Competitive Acid Blockers (P-CABs): Structure−Activity Relationship of Their Antisecretory Properties and Their Affinity toward the hERG Channel
    作者:Andreas M. Palmer、Vittoria Chiesa、Anja Schmid、Gabriela Münch、Burkhard Grobbel、Peter J. Zimmermann、Christof Brehm、Wilm Buhr、Wolfgang-Alexander Simon、Wolfgang Kromer、Stefan Postius、Jürgen Volz、Dietmar Hess
    DOI:10.1021/jm100040c
    日期:2010.5.13
    Potassium-competitive acid blockers (P-CABs) constitute a new therapeutic option for the treatment of acid-related diseases that are widespread and constitute a significant economical burden. Enantiomerically pure tetrahydrochromenoimidazoles were prepared using the readily available candidate 4 (BYK 405879) as starting material or the Noyori asymmetric reduction of ketones as key reaction. A comprehensive
    竞争性酸阻滞剂(P-CAB)构成了治疗与酸有关的疾病的新的治疗选择,这些疾病与疾病相关的疾病广泛且构成重大的经济负担。使用容易获得的候选物4制备对映体纯的四氢色氮咪唑(BYK 405879)作为起始原料或Noyori酮的不对称还原是关键反应。建立了关于5-羧酰胺和8-芳基残基对体外活性,Ghosh Schild大鼠体内酸抑制和对hERG通道的亲和力影响的综合SAR。此外,通过瘘管犬的24 h pH测量,检查了最有希望的目标化合物的抗分泌作用的功效和持续时间,与Ghosh Schild大鼠相比,观察到了明显不同的SAR。鉴定了几种与候选物4具有可比性的四氢色氮咪唑
  • THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
    申请人:Nakao Akira
    公开号:US20120196824A1
    公开(公告)日:2012-08-02
    The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
    这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式(I)的化学式,其中每个符号如本文所定义,或其药理学上可接受的盐,或其溶剂化物,作为活性成分。
  • BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND
    申请人:MITSUBISHI TANABE PHARMA CORPORATION
    公开号:US20190185479A1
    公开(公告)日:2019-06-20
    The present invention provides: a novel use of a specific bicyclic nitrogen-containing heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogen-containing heterocyclic compound having a PDE7 inhibitory effect, a method for producing the compound, a use of the compound, and a pharmaceutical composition containing the PDE7 inhibitor or the compound; and others. More specifically, the present invention provides a PDE7 inhibitor containing the compound represented by the formula (I): [wherein the symbols have the same meanings as those described in the description] or a pharmaceutically acceptable salt thereof as an active ingredient.
    本发明提供了:一种将特定的双环氮杂环化合物用作PDE7抑制剂的新用途;具有PDE7抑制作用的新型双环氮杂环化合物,一种制备该化合物的方法,该化合物的用途,以及含有PDE7抑制剂或该化合物的药物组合物;等等。更具体地,本发明提供了一种包含由下式(I)表示的化合物的PDE7抑制剂: [其中符号的含义与描述中所述的相同]或其药学上可接受的盐作为活性成分。
  • [EN] HEPATITIS B CAPSID ASSEMBLY MODULATORS<br/>[FR] MODULATEURS D'ASSEMBLAGE DE CAPSIDE DE L'HÉPATITE B
    申请人:VENATORX PHARMACEUTICALS INC
    公开号:WO2021119081A1
    公开(公告)日:2021-06-17
    Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    本文描述了乙型肝炎壳蛋白组装调节剂和包含该类化合物的药物组合物。这些化合物和组合物对于治疗乙型肝炎是有用的。
  • [EN] 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS D'ACIDE BENZOÏQUE À SUBSTITUTION 4-HÉTÉROARYLE EN TANT QU'INHIBITEURS DE RORGAMMAT ET LEURS UTILISATIONS
    申请人:MERCK SHARP & DOHME
    公开号:WO2014026327A1
    公开(公告)日:2014-02-20
    Provided are compounds according to Formula I or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
    根据公式I提供了化合物或其药用可接受的盐或溶剂。这些化合物可用于治疗RORgammaT介导的疾病或症状。
查看更多